

Paul Glue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5891591/publications.pdf>

Version: 2024-02-01

180
papers

6,773
citations

61984

43
h-index

76900

74
g-index

180
all docs

180
docs citations

180
times ranked

5785
citing authors

#	ARTICLE	IF	CITATIONS
1	Possible mechanisms for treatment heterogeneity in clinical trials of adjunctive Nâ€acetylcysteine for bipolar depression. <i>Bipolar Disorders</i> , 2022, 24, 213-213.	1.9	0
2	Use of advance directives to promote supported decision-making in mental health care: Implications of international trends for reform in New Zealand. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, , 000486742210792.	2.3	0
3	Is There Evidence for the Specificity of Closed-Loop Brain Training in the Treatment of Internalizing Disorders? A Systematic Review. <i>Frontiers in Neuroscience</i> , 2022, 16, 821136.	2.8	0
4	Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatmentâ€refractory Depression. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 720-729.	4.7	5
5	The Great Escape. Centenariansâ€™ exceptional health. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 513-520.	2.9	4
6	Influence of formulation and route of administration on ketamineâ€™s safety and tolerability: systematic review. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 671-676.	1.9	8
7	Internalize at your peril: internalizing disorders as risk factors for dementiaâ€™ cohort study. <i>GeroScience</i> , 2021, 43, 253-261.	4.6	3
8	Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. <i>Journal of Psychopharmacology</i> , 2021, 35, 137-141.	4.0	6
9	Help and Hindrances to Completion of Psychiatric Advance Directives. <i>Psychiatric Services</i> , 2021, 72, 216-218.	2.0	8
10	Olfactory shifts linked to postpartum depression. <i>Scientific Reports</i> , 2021, 11, 14947.	3.3	4
11	Right frontal anxiolytic-sensitive EEG â€thetaâ€™ rhythm in the stop-signal task is a theory-based anxiety disorder biomarker. <i>Scientific Reports</i> , 2021, 11, 19746.	3.3	15
12	Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110567.	2.7	20
13	Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. <i>Journal of Psychopharmacology</i> , 2020, 34, 267-272.	4.0	40
14	Development of the Ketamine Side Effect Tool (KSET). <i>Journal of Affective Disorders</i> , 2020, 266, 615-620.	4.1	28
15	Ketamine and neuroticism: a double-hit hypothesis of internalizing disorders. <i>Personality Neuroscience</i> , 2020, 3, e2.	1.6	10
16	Ageing badly: indicators of old-age structure in Australia and New Zealand. <i>Journal of Primary Health Care</i> , 2020, 12, 272.	0.6	5
17	Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532092247.	2.7	19
18	The content of Mental Health Advance Preference statements (MAPs): An assessment of completed advance directives in one New Zealand health board. <i>International Journal of Law and Psychiatry</i> , 2020, 68, 101537.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Aberrant salience and reward processing: a comparison of measures in schizophrenia and anxiety. <i>Psychological Medicine</i> , 2020, 51, 1-9.	4.5	10
20	Ascendingâ€Dose Study of Controlledâ€Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 751-757.	2.0	7
21	Fatigue, sleep and depression: An exploratory interRAI study of older adults.. <i>Psychiatry Research</i> , 2020, 284, 112772.	3.3	8
22	Anterior Cingulate Cortex Implants for Alcohol Addiction: A Feasibility Study. <i>Neurotherapeutics</i> , 2020, 17, 1287-1299.	4.4	12
23	Progesterone loading as a strategy for treating postpartum depression. <i>Human Psychopharmacology</i> , 2020, 35, e2731.	1.5	8
24	Human anxiety-specific â€œthetaâ€ occurs with selective stopping and localizes to right inferior frontal gyrus.. <i>Behavioral Neuroscience</i> , 2020, 134, 547-555.	1.2	9
25	Advance Directives: Another Gap in Services for People With Borderline Personality Disorder. <i>Psychiatric Services</i> , 2020, 71, 528-529.	2.0	2
26	The clinical toxicology of cannabis. <i>New Zealand Medical Journal</i> , 2020, 133, 96-103.	0.5	1
27	Service user, whānau and peer support workersâ€™ perceptions of advance directives for mental health. <i>International Journal of Mental Health Nursing</i> , 2019, 28, 1296-1305.	3.8	10
28	Screaming behaviour in response to electroconvulsive treatment: psychogeriatric note on a patient with Alzheimer's disease. <i>Psychogeriatrics</i> , 2019, 19, 626-627.	1.2	1
29	A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression â€œ the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 260-261.	4.0	0
30	Low-risk and high-risk groups matter in suicide risk. <i>Psychological Medicine</i> , 2019, 49, 879-880.	4.5	0
31	Dissociation after ketamine dosing: Is the CADSS fit for purpose?. <i>Journal of Affective Disorders</i> , 2019, 244, 239-240.	4.1	6
32	Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients. <i>EBioMedicine</i> , 2018, 27, 134-137.	6.1	10
33	Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. <i>Drug Delivery and Translational Research</i> , 2018, 8, 780-786.	5.8	17
34	Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 717-724.	2.1	26
35	Repeated intranasal ketamine for treatment-resistant depression â€œ the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2018, 32, 397-407.	4.0	66
36	Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. <i>Journal of Psychopharmacology</i> , 2018, 32, 663-667.	4.0	58

#	ARTICLE	IF	CITATIONS
37	Comparison of Psychosocial Variables Associated With Loneliness in Centenarian vs Elderly Populations in New Zealand. <i>JAMA Network Open</i> , 2018, 1, e183880.	5.9	20
38	The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats. <i>Journal of Psychopharmacology</i> , 2018, 32, 1127-1132.	4.0	8
39	How comprehensive is suicide risk assessment in the emergency department?. <i>New Zealand Medical Journal</i> , 2018, 131, 11-13.	0.5	0
40	A MAP to mental health: the process of creating a collaborative advance preferences instrument. <i>New Zealand Medical Journal</i> , 2018, 131, 18-26.	0.5	6
41	Comments on Cooper et al.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 489-489.	2.6	2
42	Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. <i>Journal of Psychopharmacology</i> , 2017, 31, 1302-1305.	4.0	83
43	Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1199-1209.	1.2	85
44	Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. <i>Journal of Psychopharmacology</i> , 2017, 31, 1306-1311.	4.0	16
45	Ketamine and Suicidal Ideation. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 282-283.	1.4	3
46	Anterior Cingulate Implant for Obsessive-Compulsive Disorder. <i>World Neurosurgery</i> , 2017, 97, 754.e7-754.e16.	1.3	19
47	Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 960-965.	2.0	11
48	Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 48-56.	4.5	160
49	Effects of low dose ibogaine on subjective mood state and psychological performance. <i>Journal of Ethnopharmacology</i> , 2016, 189, 10-13.	4.1	23
50	Adjunctive pregabalin vs gabapentin for focal seizures. <i>Neurology</i> , 2016, 87, 1242-1249.	1.1	17
51	Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. <i>Australasian Psychiatry</i> , 2016, 24, 598-601.	0.7	42
52	Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 460-468.	1.6	30
53	Psychosurgery Reduces Uncertainty and Increases Free Will? A Review. <i>Neuromodulation</i> , 2016, 19, 239-248.	0.8	40
54	Testing an anxiety process biomarker: Generalisation from an auditory to a visual stimulus. <i>Biological Psychology</i> , 2016, 117, 50-55.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv124.	2.1	175
56	Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. <i>New Zealand Medical Journal</i> , 2016, 129, 37-40.	0.5	0
57	Psychiatric assessment is a necessary part of humane care. <i>BMJ, The</i> , 2015, 351, h4315.	6.0	0
58	An improved human anxiety process biomarker: characterization of frequency band, personality and pharmacology. <i>Translational Psychiatry</i> , 2015, 5, e699-e699.	4.8	28
59	Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1215-1220.	2.3	24
60	Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 189-194.	2.0	43
61	Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20µmg dose of ibogaine in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 680-687.	2.0	28
62	Why academic psychiatry is endangered. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 9-12.	2.3	25
63	Implementation of the 2013 Psychoactive Substances Act and mental health harms from synthetic cannabinoids. <i>New Zealand Medical Journal</i> , 2015, 128, 15-8.	0.5	22
64	Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. <i>Drug Discoveries and Therapeutics</i> , 2014, 8, 89-95.	1.5	12
65	“Violence is Not Part of Our Job”: A Thematic Analysis of Psychiatric Mental Health Nurses’ Experiences of Patient Assaults from a New Zealand Perspective. <i>Issues in Mental Health Nursing</i> , 2014, 35, 647-655.	1.2	69
66	When the mandatory second opinion fails to approve compulsory treatment. <i>Australasian Psychiatry</i> , 2014, 22, 337-340.	0.7	1
67	Electroconvulsive therapy use in Otago, New Zealand: a 10-year retrospective audit of patient-level treatment data. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 548-553.	2.3	3
68	Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 579-584.	2.6	70
69	Long-Lasting Effects of a Single Subcutaneous Dose of Ketamine for Treating Melancholic Depression: A Case Report. <i>Biological Psychiatry</i> , 2014, 76, e1-e2.	1.3	32
70	Oxytocin improves emotion recognition for older males. <i>Neurobiology of Aging</i> , 2014, 35, 2246-2248.	3.1	49
71	Impact of Dietary Benzoic Acid on Treatment Response in Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 1298.	11.0	1
72	Postgraduation retention of medical students from Otago and Auckland medical programmes. <i>New Zealand Medical Journal</i> , 2014, 127, 47-54.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Influence of rural background and rural medical training on postgraduate medical training and location in New Zealand. <i>New Zealand Medical Journal</i> , 2014, 127, 12-6.	0.5	2
74	Systematic review of cognitive development across childhood in Down syndrome: implications for treatment interventions. <i>Journal of Intellectual Disability Research</i> , 2013, 57, 306-318.	2.0	64
75	Anti-anxiety drugs reduce conflict-specific "A possible human anxiety-specific biomarker. <i>Journal of Affective Disorders</i> , 2013, 148, 104-111.	4.1	47
76	Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 710-727.	2.3	100
77	Quantification of Brain Voriconazole Levels in Healthy Adults Using Fluorine Magnetic Resonance Spectroscopy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5271-5276.	3.2	18
78	Case Report: Long-Term Mood Response To Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced Cancer. <i>Journal of Palliative Medicine</i> , 2013, 16, 719-720.	1.1	15
79	Hospitalisation associated with use of the synthetic cannabinoid K2. <i>New Zealand Medical Journal</i> , 2013, 126, 18-23.	0.5	29
80	Mood and Pain Responses to Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced Cancer. <i>Journal of Palliative Medicine</i> , 2012, 15, 400-403.	1.1	42
81	Comparative efficacy of anti-manic drugs in acute mania. <i>Lancet, The</i> , 2012, 379, 892.	13.7	1
82	Evaluation of Bioequivalence Between Clozapine Suspension and Tablet Formulations. <i>Clinical Drug Investigation</i> , 2012, 32, 723-727.	2.2	13
83	Benzodiazepines for generalised anxiety disorder (GAD). <i>The Cochrane Library</i> , 2012, , .	2.8	1
84	Optimal treatment of social phobia: systematic review and meta-analysis. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 203.	2.2	55
85	Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 415-418.	1.9	19
86	Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 229-236.	2.0	92
87	Dose- and Exposure-Response to Ketamine in Depression. <i>Biological Psychiatry</i> , 2011, 70, e9-e10.	1.3	42
88	Switching from Quetiapine to Ziprasidone. <i>Journal of Psychiatric Practice</i> , 2011, 17, 100-109.	0.7	15
89	Study design and patient characteristics and outcome in acute mania clinical trials. <i>Bipolar Disorders</i> , 2011, 13, 125-132.	1.9	11
90	Comparison of pharmacokinetic variability of fesoterodine <i>vs.</i> tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 226-234.	2.4	24

#	ARTICLE	IF	CITATIONS
91	Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania – A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2011, 134, 14-19.	4.1	27
92	An Eight-Week Trial Investigating the Efficacy and Tolerability of Atorvastatin for Children and Adolescents With Heterozygous Familial Hypercholesterolemia. <i>Pediatric Cardiology</i> , 2011, 32, 433-441.	1.3	25
93	Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 731-738.	2.0	7
94	Off-label use of quetiapine in New Zealand—a cause for concern?. <i>New Zealand Medical Journal</i> , 2011, 124, 10-3.	0.5	3
95	New Prospects for the Drug Treatment of Generalized Anxiety Disorder – A Systematic Review. <i>Current Drug Therapy</i> , 2010, 5, 86-94.	0.3	2
96	The pharmacokinetic profile of fesoterodine 8Åmg with daytime or nighttime dosing. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 171-176.	1.9	13
97	Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – A meta-analysis. <i>Journal of Affective Disorders</i> , 2010, 123, 9-16.	4.1	59
98	Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 51-57.	2.4	28
99	Pregabalin for painful HIV neuropathy. <i>Neurology</i> , 2010, 74, 413-420.	1.1	185
100	Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive Disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 697-705.	2.3	83
101	Considerations for the Design and Conduct of a Pharmacovigilance Study Involving Mass Drug Administration in a Resource-Constrained Setting. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e564.	3.0	4
102	Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 291-300.	2.0	18
103	Can Drug Treatments Enhance Learning in Subjects with Intellectual Disability?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 899-904.	2.3	6
104	A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. <i>BMC Medical Research Methodology</i> , 2009, 9, 55.	3.1	54
105	Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 682-689.	2.4	9
106	Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. <i>Schizophrenia Research</i> , 2009, 111, 39-45.	2.0	15
107	The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 58-62.	2.2	45
108	Response to – Feedback to Tolterodine QT – <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 233-233.	4.7	1

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 531-539.	2.4	40
110	Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 523-530.	2.4	32
111	The Effect of Azithromycin on Ivermectin Pharmacokinetics—A Population Pharmacokinetic Model Analysis. <i>PLoS Neglected Tropical Diseases</i> , 2008, 2, e236.	3.0	32
112	Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial*. <i>Critical Care Medicine</i> , 2007, 35, 1863-1868.	0.9	28
113	Thorough QT Study with Recommended and Supratherapeutic Doses of Tolterodine. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 377-385.	4.7	81
114	Model-based Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 21-32.	4.7	394
115	PHARMACOKINETICS OF AZITHROMYCIN AND THE COMBINATION OF IVERMECTIN AND ALBENDAZOLE WHEN ADMINISTERED ALONE AND CONCURRENTLY IN HEALTHY VOLUNTEERS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 76, 1153-1157.	1.4	33
116	Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 76, 1153-7.	1.4	20
117	The effect of food on the absorption of oral ziprasidone. <i>Psychopharmacology Bulletin</i> , 2007, 40, 58-68.	0.0	27
118	Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1030-1037.	2.0	25
119	Effect of Food on the Bioavailability of Amlodipine Besylate/Atorvastatin Calcium Combination Tablet. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1212-1216.	2.0	25
120	Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers. <i>American Journal of Therapeutics</i> , 2006, 13, 418-422.	0.9	19
121	Bioavailability of Amlodipine Besylate Following Oral Administration as a Tablet Dispersed in Applesauce. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 695-698.	2.0	5
122	Single-dose pharmacokinetics and tolerability of pegylated interferon- β in young and elderly healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 131-134.	2.4	26
123	Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 349-361.	4.7	48
124	Single-Dose Pharmacokinetics and Safety of Pegylated Interferon- β in Patients with Chronic Renal Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1109-1115.	2.0	74
125	Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 193-195.	0.7	100
126	Population pharmacokinetic analysis of pegylated interferon alfa- β and interferon alfa- β in patients with chronic hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 407-421.	4.7	42

#	ARTICLE	IF	CITATIONS
127	Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 555-565.	2.0	163
128	The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 417-421.	2.4	38
129	A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C. <i>Hepatology</i> , 2000, 32, 647-653.	7.3	234
130	Pegylated interferon- α 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 556-567.	4.7	452
131	Pharmacokinetics and Absolute Bioavailability of Ribavirin in Healthy Volunteers as Determined by Stable-Isotope Methodology. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2451-2456.	3.2	98
132	Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment. <i>Cellular and Molecular Neurobiology</i> , 1999, 19, 309-323.	3.3	55
133	Changes in Serum Hepatitis C Virus RNA in Interferon Nonresponders Retreated With Interferon Plus Ribavirin. <i>Journal of Clinical Gastroenterology</i> , 1999, 28, 313-316.	2.2	11
134	The clinical pharmacology of ribavirin. <i>Seminars in Liver Disease</i> , 1999, 19 Suppl 1, 17-24.	3.6	71
135	Intestinal absorption of ribavirin is preferentially mediated by the Na ⁺ -nucleoside purine (N1) transporter. <i>Pharmaceutical Research</i> , 1998, 15, 950-952.	3.5	79
136	Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.4	124
137	Ribavirin and interferon alfa α 2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 563-570.	2.4	133
138	Pharmacokinetic Interactions with Felbamate. <i>Clinical Pharmacokinetics</i> , 1997, 33, 214-224.	3.5	57
139	Effect of Felbamate on the Pharmacokinetics of Lamotrigine. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 634-638.	2.0	22
140	Effect of Felbamate on Valproic Acid Disposition in Healthy Volunteers: Inhibition of beta-Oxidation. <i>Epilepsia</i> , 1996, 37, 91-97.	5.1	56
141	Psychiatry, psychopharmacology and P-450s. <i>Human Psychopharmacology</i> , 1996, 11, 97-114.	1.5	36
142	Pharmacodynamic Effects of Interferon ALFA-2b in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 205-205.	4.7	1
143	The Effect of Age on the Apparent Clearance of Felbamate: A Retrospective Analysis Using Nonlinear Mixed-Effects Modeling. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 19-29.	2.0	27
144	Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 383-389.	4.7	28

#	ARTICLE	IF	CITATIONS
145	Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 523-531.	4.7	87
146	Effects of felbamate on the pharmacokinetics of phenobarbital. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 279-287.	4.7	62
147	The relationship between benzodiazepine receptor sensitivity and neuroticism. <i>Journal of Anxiety Disorders</i> , 1995, 9, 33-45.	3.2	23
148	Saccadic eye movement parameters in normal subjects. <i>Electroencephalography and Clinical Neurophysiology</i> , 1993, 86, 69-74.	0.3	65
149	Challenge tests: Assessment of the noradrenergic and gaba systems in depression and anxiety disorders. <i>Molecular Aspects of Medicine</i> , 1992, 13, 221-247.	6.4	18
150	Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: Preliminary open trial of the effects of acute and chronic idazoxan. <i>Psychoneuroendocrinology</i> , 1992, 17, 261-266.	2.7	7
151	Flumazenil and saccadic eye movements in patients with panic disorder and normal controls. <i>Human Psychopharmacology</i> , 1992, 7, 45-50.	1.5	7
152	Benzodiazepine receptor sensitivity in panic disorder. <i>Lancet, The</i> , 1991, 337, 563.	13.7	6
153	Pharmacology of saccadic eye movements in man. <i>Psychopharmacology</i> , 1991, 105, 368-373.	3.1	34
154	Irritability in panic disorder: Effects of imipramine treatment. <i>Human Psychopharmacology</i> , 1991, 6, 49-52.	1.5	3
155	Pharmacology of saccadic eye movements in man. <i>Psychopharmacology</i> , 1991, 105, 361-367.	3.1	83
156	Merck, Sharp & Dohme Prize for Young Psychopharmacologists. <i>Journal of Psychopharmacology</i> , 1991, 5, 377-387.	4.0	35
157	Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. <i>Journal of Psychopharmacology</i> , 1991, 5, 396-403.	4.0	17
158	Overexcitement and Disinhibition. <i>British Journal of Psychiatry</i> , 1990, 157, 491-499.	2.8	84
159	Regional neurotransmitter responses after acute and chronic electroconvulsive shock. <i>Psychopharmacology</i> , 1990, 100, 60-65.	3.1	51
160	Lithium Treatment Effect on Serotonin Function. <i>Archives of General Psychiatry</i> , 1990, 47, 289.	12.3	1
161	Flumazenil Provocation of Panic Attacks. <i>Archives of General Psychiatry</i> , 1990, 47, 917.	12.3	261
162	Neuropharmacological and Clinical Aspects of Alcohol Withdrawal. <i>Annals of Medicine</i> , 1990, 22, 275-281.	3.8	26

#	ARTICLE	IF	CITATIONS
163	Oxytocin and vasopressin responses to ECT. <i>Psychiatry Research</i> , 1990, 32, 201-202.	3.3	11
164	Lactate-induced electrolyte changes in the cerebrospinal fluid of rabbits. <i>Biological Psychiatry</i> , 1990, 27, 104-108.	1.3	6
165	Neurochemical insights into alcohol kindling. <i>Human Psychopharmacology</i> , 1989, 4, 157-158.	1.5	3
166	Studies of Alpha-2-Adrenoceptor Function in Abstinent Alcoholics. <i>Addiction</i> , 1989, 84, 97-102.	3.3	27
167	Clinical pharmacology of anxiolytics and antidepressants: A psychopharmacological perspective. , 1989, 44, 309-334.		66
168	Rapid cycling affective disorders in the mentally retarded. <i>Biological Psychiatry</i> , 1989, 26, 250-256.	1.3	51
169	Monoamine Oxidase Inhibitors: Rehabilitation from Recent Research?. <i>British Journal of Psychiatry</i> , 1989, 154, 287-291.	2.8	40
170	Aspects of alpha-2-adrenoceptor function in normal volunteers. <i>Human Psychopharmacology</i> , 1988, 3, 235-245.	1.5	12
171	The hypothermic response to clonidine is absent in alcohol withdrawal but returns in abstinence. <i>Biological Psychiatry</i> , 1988, 24, 102-104.	1.3	17
172	Psychopathology in Adult Mentally Handicapped Hospital Patients. <i>Australian and New Zealand Journal of Psychiatry</i> , 1988, 22, 312-315.	2.3	7
173	Clonidine challenge testing of alpha-2-adrenoceptor function in man: the effects of mental illness and psychotropic medication. <i>Journal of Psychopharmacology</i> , 1988, 2, 119-137.	4.0	21
174	alpha-2-Adrenoceptor Function in Alcohol Withdrawal: A Pilot Study of the Effects of IV Clonidine in Alcoholics and Normals. <i>Alcoholism: Clinical and Experimental Research</i> , 1988, 12, 14-18.	2.4	61
175	Psychotherapy and Dysmorphophobia: A Case Report. <i>British Journal of Psychiatry</i> , 1988, 152, 271-274.	2.8	32
176	Platelet Monamine Receptor Binding in Alcoholics During Withdrawal. <i>Addiction</i> , 1987, 82, 1253-1255.	3.3	4
177	Clonidine in alcohol withdrawal: a pilot study of differential symptom responses following i.v. clonidine. <i>Alcohol and Alcoholism</i> , 1987, 22, 161-6.	1.6	9
178	Monoamines and Alcohol. <i>Addiction</i> , 1986, 81, 327-338.	3.3	41
179	Benzodiazepines for generalised anxiety disorder (GAD). <i>The Cochrane Library</i> , 0, , .	2.8	0
180	Right Frontal Theta: Is It a Response Biomarker for Ketamine's Therapeutic Action in Anxiety Disorders?. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	0